ADMA Biologics, Inc. (ADMA)

In the past six months, ADMA Biologics' stock has experienced a significant pullback from its mid-2025 highs, trading near its 52-week low. Technical indicators suggest this decline is largely due to panic selling or investor capitulation. Despite the stock's performance, the company reported strong operational results, with Q2 2025 EPS of $0.15, surpassing the consensus estimate. Revenue for the quarter reached $121.98 million, exceeding expectations and representing a 13.8% year-over-year increase. Analysts generally maintain a Buy consensus rating for ADMA Biologics, with a target price of $27.67.

Based on available information, there is no explicit mention of significant demand seasonality for ADMA Biologics' specific products and services. The broader biosimilar contract manufacturing market, in which ADMA Biologics operates, is driven by the increasing prevalence of chronic diseases, suggesting a relatively consistent demand rather than strong seasonal fluctuations.

ADMA Biologics, Inc. is a commercial biopharmaceutical company focused on developing, manufacturing, and marketing specialty plasma-derived biologics to treat immunodeficient patients and individuals susceptible to certain infectious diseases. The company operates in the Medical sector, specifically in the Medical - Biomedical and Genetics industry. Its major FDA-approved products include BIVIGAM and ASCENIV, both indicated for the treatment of primary humoral immunodeficiency (PI). ADMA Biologics also produces NABI-HB to provide enhanced immunity against the hepatitis B virus and functions as an FDA-approved source plasma collector through its subsidiary, ADMA BioCenters.

ADMA Biologics is headquartered in Ramsey, New Jersey, USA, with another office in Boca Raton, Florida. The company develops, manufactures, and markets its products in the United States and internationally. Its ADMA BioCenters subsidiary operates FDA-approved source plasma collection centers across the United States.

In the past year, ADMA Biologics has maintained a generally positive brand reputation, supported by favorable analyst sentiment and strong operational performance. The company has received a consensus Buy rating from analysts, with a target price of $27.67. ADMA Biologics has demonstrated strong financial performance, with improved guidance for 2025 and 2026, and fiscal year 2024 marked its most profitable year to date and fourth consecutive year of record growth. The anticipated approval of an immunoglobulin (Ig) yield enhancement process is expected to significantly boost production output, leading to sustained gross margin expansion and higher net income starting in early 2026. Recent long-term plasma contracts have mitigated supply chain concerns, supporting the growth potential of its products like ASCENIV. The company is recognized as one of the fastest-growing in the specialty biopharma sector. However, a potential risk to its reputation and sentiment is a heavy reliance on just two primary products and the possibility of operational challenges disrupting growth expectations. While the company's one-year total shareholder return shows some near-term pressure at -7.6%, its long-term returns over three and five years are robust, at 438% and 630% respectively.

ADMA Biologics has a significant level of institutional ownership, with approximately 88.42% of the company's stock held by institutional shareholders. Major institutional owners include BlackRock Inc., Vanguard Group Inc., and Invesco Ltd. Insiders of ADMA Biologics own about 23.45% of the company, with key individual and insider shareholders including Perceptive Advisors LLC and Divestiture Trust Biotest. Retail investor ownership figures vary across sources.